Currently out of the existing stock ratings of Difei Yang, 176 are a BUY (88.44%), 21 are a HOLD (10.55%), 2 are a SELL (1.01%).

Difei Yang

Work Performance Price Targets & Ratings Chart

Analyst Difei Yang, currently employed carries an average stock price target met ratio of 48.53% that have a potential upside of 45.37% achieved within 277 days. Previously, Difei Yang worked at MIZUHO.

Difei Yang’s has documented 419 price targets and ratings displayed on 29 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 24-Jun-2022.

Wall Street Analyst Difei Yang

Analyst best performing recommendations are on RLYP (RELYPSA).
The best stock recommendation documented was for RLYP (RELYPSA) at 7/18/2016. The price target of $26 was fulfilled within 3 days with a profit of $5.75 (28.4%) receiving and performance score of 94.65.

Average potential price target upside

AERI Aerie Pharmaceuticals . AKBA Akebia Ther BLUE Bluebird bio CNCE Concert Pharmaceuticals FGEN FibroGen FRLN Freeline Therapeutics Holdings Plc HZNP Horizon Pharma PLC MNTA Momenta Pharmaceuticals NKTR Nektar Therapeutics NVCR Novocure Ltd RLYP Relypsa RVNC Revance The SELB Selecta Biosciences SRPT Sarepta Therapeutics XERS Xeris Pharmaceuticals ZGNX Zogenix MGTA Magenta Therapeutics ONCE Spark Therapeutics PTX Pernix Therapeutics Holdings AVRO AVROBIO HRTX Heron Therapeuti ALDR Alder BioPharmaceuticals BOLD Audentes Therapeutics EOLS Evolus ABEO Abeona Therapeutics AKAO Achaogen MRNS Marinus Pharmaceuticals VNDA Vanda Pharmaceuticals QURE Uniqure NV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$13

2 years 2 months 15 days ago
(29-Aug-2022)

1/5 (20%)

$4.7 (56.63%)

176

Hold

2 years 2 months 20 days ago
(24-Aug-2022)

0/1 (0%)

$6.53 (25.64%)

Hold

$20

2 years 2 months 20 days ago
(24-Aug-2022)

0/4 (0%)

$14.21 (245.42%)

Buy

$15.25

$27

2 years 2 months 21 days ago
(23-Aug-2022)

7/11 (63.64%)

$0.09 (0.59%)

149

Hold

$15.25

$30

2 years 2 months 21 days ago
(23-Aug-2022)

1/3 (33.33%)

$0.09 (0.59%)

48

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Difei Yang?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?